Under construction – not a live service
Sign in
Taking people in SwedenPhase 4

Care bundle tested for brain bleeds caused by spontaneous intracerebral hemorrhage

Tests a structured care bundle against standard care in adults with brain bleeding.

Plain-language title generated from the registry record
Registry title: International Care Bundle Evaluation in Cerebral Hemorrhage Research

Key facts

Where
Eksjö, Gothenburg, Hässleholm, Helsingborg, Huddinge, Jönköping, Kalmar, Karlskrona, Karlstad, Köping, Kristianstad, Kungälv, Linköping, Ljungby, Lund, Malmö, Mölndal, Örebro, Oskarshamn, Östersund, Skövde, Stockholm, Sundsvall, Trollhättan, Umeå, Uppsala, Varberg, Värnamo, Västerås, Vaxjo, and Ystad, SwedenSee the 38 sites
Phase
Phase 4

Where in Sweden

  • Höglandssjukhuset i EksjöEksjö, SwedenTaking people
  • Östra SjukhusetGothenburg, SwedenTaking people
  • Sahlgrenska UniversitetssjukhusetGothenburg, SwedenTaking people
  • Hässleholms sjukhusHässleholm, SwedenTaking people
  • Helsingborgs lasarettHelsingborg, SwedenTaking people
  • Karolinska Universitetssjukhuset HuddingeHuddinge, SwedenTaking people
  • Lanssjukhuset RyhovJönköping, SwedenTaking people
  • Länssjukhuset KalmarKalmar, SwedenTaking people
  • BlekingesjukhusetKarlskrona, SwedenTaking people
  • Blekingesjukhuset KarlskronaKarlskrona, SwedenTaking people
  • Centralsjukhuset KarlstadKarlstad, SwedenTaking people
  • Västmanlands sjukhus KöpingKöping, SwedenTaking people
  • Centralsjukhuset KristianstadKristianstad, SwedenTaking people
  • Kungälvs sjukhusKungälv, SwedenTaking people
  • Univeristetssjukhuset LinköpingLinköping, SwedenTaking people
  • Ljungby LasarettLjungby, SwedenTaking people
  • Skåne University Hospital LundLund, SwedenTaking people
  • Skåne University Hospital Lund Neurosurgery deptLund, SwedenTaking people
  • Region Skåne, Skåne University Hospital in Malmö, Department of NeurologyMalmö, SwedenTaking people
  • Mölndals SjukhusMölndal, SwedenTaking people
  • Universitetssjukhuset ÖrebroÖrebro, SwedenTaking people
  • Oskarshamn SjukhusOskarshamn, SwedenTaking people
  • Östersunds LasarettÖstersund, SwedenTaking people
  • Skaraborgs sjukhus SkövdeSkövde, SwedenTaking people
  • Capio St Görans sjukhusStockholm, SwedenTaking people
  • Danderyds sjukhusStockholm, SwedenTaking people
  • Karolinska Universitetssjukhuset SolnaStockholm, SwedenTaking people
  • SödersjukhusetStockholm, SwedenTaking people
  • Länssjukhuset SundsvallSundsvall, SwedenTaking people
  • Norra Älvsborgs LänssjukhusTrollhättan, SwedenTaking people
  • Norrlands universitetssjukhusUmeå, SwedenTaking people
  • Akademiska Sjukhuset UppsalUppsala, SwedenTaking people
  • Lasarettet i EnköpingUppsala, SwedenTaking people
  • Hallands sjukhus VarbergVarberg, SwedenTaking people
  • Värnamo sjukhusVärnamo, SwedenTaking people
  • VästeråsVästerås, SwedenTaking people
  • Centrallasarettet VäxjöVaxjo, SwedenTaking people
  • Ystads lasarettYstad, SwedenTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Region Skane
Trial code
NCT06429332
Record updated
22 May 2026
Original description
Spontaneous intracerebral haemorrhage (ICH) accounts for approximately 10-15% of all strokes but stands for 50% of stroke-related morbidity and mortality. Approximately half of all patients with ICH have a decreased level of consciousness at hospital admission. Despite this, intensive care and neurosurgical interventions are uncommon. A study conducted in low- and middle-income countries has demonstrated a beneficial effect of a treatment package consisting of early intensive blood pressure lowering, as well as the treatment of pyrexia and elevated blood glucose levels. The I-CATCHER team is now planning to conduct a similar study in Sweden and Australia, as well as in other high-income countries. The study has a clear focus on implementation, aiming to improve treatment and prognosis for patients with ICH within a few years. The purpose of I-CATCHER is to investigate whether a structured treatment package (Care Bundle) improves 3-month prognosis in patients with spontaneous ICH compared to standard care.Read full original descriptionShow less

International Care Bundle Evaluation in Cerebral Hemorrhage Research - a Batched Parallel Cluster-randomized Trial With a Baseline Period

Spontaneous intracerebral haemorrhage (ICH) accounts for approximately 10-15% of all strokes but stands for 50% of stroke-related morbidity and mortality. Approximately half of all patients with ICH have a decreased level of consciousness at hospital admission. Despite this, intensive care and neurosurgical interventions are uncommon. A study conducted in low- and middle-income countries has demonstrated a beneficial effect of a treatment package consisting of early intensive blood pressure lowering, as well as the treatment of pyrexia and elevated blood glucose levels. The I-CATCHER team is now planning to conduct a similar study in Sweden and Australia, as well as in other high-income countries. The study has a clear focus on implementation, aiming to improve treatment and prognosis for patients with ICH within a few years. The purpose of I-CATCHER is to investigate whether a structured treatment package (Care Bundle) improves 3-month prognosis in patients with spontaneous ICH compared to standard care.

Inclusion: Adults (age ≥18 years); Non-contrast computerized tomography (NCCT) imaging-verified diagnosis of spontaneous intracerebral haemorrhage; ≤24 hours from symptom onset or presumed symptom onset (last seen well).

Exclusion: Previous care limitation; End-stage comorbidity with short life-expectancy (<6 m; e.g. terminal cancer); ICH caused by brain tumor or cerebral venous thrombosis; Clinical signs of brain herniation at first presentation (unresponsive patient with bilaterally fixed, maximally dilated pupils); Pregnant women beyond 22 weeks gestation may only be included after thorough discussion with an obstetrician to determine risks vs benefit.

ClinicalTrials.gov NCT06429332